T-Therapeutics Secures $91M Series A Extension to Advance TCR-CD3 Bispecifics for Oncology and Autoimmune Diseases, Backed by Tencent and Sanofi

On November 13, in Cambridge, UK, T-Therapeutics, a biotechnology company developing next-generation T-cell receptor (TCR) therapies for cancer and autoimmune diseases, announced the successful expansion of its Series A financing, raising $32 million. Following the initial raise of $59 million, the total amount of Series A financing has reached $91 million. The company...Spun off from the University of Cambridge,The company was founded to harness the power of T-cell biology to create safe and effective treatments for cancer and autoimmune diseases.

New investor Tencent andBGFJoined in the Series A investment, in addition to all the existing major shareholders Sofinnova Partners, F-Prime、Digitalis Ventures、Cambridge Innovation Capital、Sanofi VenturesAndUniversity of Cambridge Venture Fund。

T-Therapeutics will use the additional proceeds to advance its first-in-class TCR-CD3 bispecific products in oncology and autoimmune diseases into clinical trials, including further exploration of new therapeutic strategies such as T cell subset depletion. The leading asset of T-Therapeutics in the field of oncology utilizes a pan-tumor driver target, applicable to various types of solid tumors. Its leading immunology program is a pan-autoimmune bispecific designed to achieve precise immune resetting by selectively depleting pathogenic immune cells.

Theodora Harold, CEO of T-Therapeutics, stated:"Our transformative drugs address upstream disease drivers that may have pan-indicative effects. We are thrilled to significantly increase our Series A financing, which we believe is a strong validation of our technology and progress to date. I would like to thank Tencent and BGF for their confidence in our potential, as well as all our existing investors for their continued support."

T-Therapeutics' TCR platform OpTiMus® can generate an almost infinite number of high-specificity, fully human TCRs, enabling access to validated but previously undruggable intracellular targets. The company also leverages its proprietary next-generation CD3 T cell Engagers (TCE).TCECarefully designed with high efficiency, excellent safety, and favorable pharmacokinetics. OpTiMus-derived TCR combines with proprietary TCE to form a first-class bispecific candidate drug. T-Therapeutics' pipeline focuses on upstream disease drivers with pan-indication potential, bringing significant clinical benefits to patients.

Graziano Seghezzi, Managing Partner of Sofinnova Partners, stated:"Existing investors co-founded T-Therapeutics to push the boundaries of bispecific technology. This additional funding allows us to expand into T cell subset depletion, one of the most exciting areas in immunology, while continuing to advance our oncology programs. We are now ideally positioned to address two broad disease areas with significant unmet medical needs: cancer and autoimmune diseases, with a platform capable of unlocking previously considered undruggable targets."

BGF partner Luke Rajah said:"This is a leadership team with an outstanding track record in building successful drug discovery businesses and translating science into medicines. Backed by a consortium of world-class life science investors, T-Therapeutics is uniquely positioned to unlock previously undruggable targets with its best-in-class bispecifics. We are proud to support the team and help advance their clinical programs."

Follow the official account below to explore the world with you!